However, it: Only results in modest weight loss (~5-7% body weight) Can cause gastrointestinal distress (diarrhea, nausea) Works best for those with insulin resistance rather than general obesity How GLP-1 and GIP Medications Offer Superior Weight Loss GLP-1 (Glucagon-Like Peptide-1) and GIP (Gastric Inhibitory Polypeptide) receptor agonists represent a new era in obesity treatment , working through multiple mechanisms to promote substantial and sustainable weight loss : Enhanced Appetite Suppression and Fullness GLP-1/GIP medications mimic natural gut hormones that regulate hunger and satiety, leading to: Significantly reduced appetite and cravings Longer-lasting fullness after meals No stimulant effects or addiction potential More Effective Weight Loss Compared to older medications, GLP-1 and GIP drugs produce greater and sustained weight loss : Tirzepatide (Mounjaro/Zepbound): 20-25% total body weight loss Semaglutide (Ozempic/Wegovy): 15-20% total body weight loss Phentermine & Topamax (Qsymia): 5-10% weight loss Metformin: 5-7% weight loss Long-Term Safety and Cardiometabolic Benefits Unlike Phentermine, which is only approved for short-term use , GLP-1/GIP medications are safe for long-term weight management

But its also important to take a look at the different types in relation to your #goals
After more than a decade on the market, long-term studies revealed increased risk of heart attack and stroke, leading to its global withdrawal in 2010
Additionally, maintaining a steady, moderate weight loss pace (if weight reduction is a goal) can prevent the rapid changes in bile chemistry that contribute to gallstone formation
Understanding its mechanism is critical for patients and even more so for aesthetic professionals treating the side effects of rapid fat loss